Your browser doesn't support javascript.
loading
Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction.
Cristiano, C; Cuozzo, M; Coretti, L; Liguori, F M; Cimmino, F; Turco, L; Avagliano, C; Aviello, G; Mollica, M P; Lembo, F; Russo, R.
Afiliação
  • Cristiano C; Department of Pharmacy, University of Naples Federico II, Italy; Task Force on Microbiota Studies University "Federico II" of Naples, Napoli, Italy. Electronic address: claudia.cristiano@unina.it.
  • Cuozzo M; Department of Pharmacy, University of Naples Federico II, Italy.
  • Coretti L; Department of Pharmacy, University of Naples Federico II, Italy; Task Force on Microbiota Studies University "Federico II" of Naples, Napoli, Italy.
  • Liguori FM; Department of Pharmacy, University of Naples Federico II, Italy.
  • Cimmino F; Department of Biology, University of Naples Federico II, Italy.
  • Turco L; Department of Pharmacy, University of Naples Federico II, Italy; Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Italy.
  • Avagliano C; Department of Pharmacy, University of Naples Federico II, Italy.
  • Aviello G; Department of Pharmacy, University of Naples Federico II, Italy.
  • Mollica MP; Department of Biology, University of Naples Federico II, Italy; Task Force on Microbiota Studies University "Federico II" of Naples, Napoli, Italy.
  • Lembo F; Department of Pharmacy, University of Naples Federico II, Italy; Task Force on Microbiota Studies University "Federico II" of Naples, Napoli, Italy.
  • Russo R; Department of Pharmacy, University of Naples Federico II, Italy; Task Force on Microbiota Studies University "Federico II" of Naples, Napoli, Italy.
Biomed Pharmacother ; 153: 113528, 2022 Sep.
Article em En | MEDLINE | ID: mdl-36076609
ABSTRACT
Paclitaxel (PTX) is one of the most broadly used chemotherapeutic agents for the treatment of several tumor types including ovarian, breast, and non-small cell lung cancer. However, its use is limited by debilitating side effects, involving both gastrointestinal and behavioral dysfunctions. Due to growing evidence showing a link between impaired gut function and chemotherapy-associated behavioral changes, the aim of this study was to identify a novel therapeutic approach to manage PTX-induced gut and brain comorbidities. Mice were pre-treated with sodium butyrate (BuNa) for 30 days before receiving PTX. After 14 days, mice underwent to behavioral analysis and biochemical investigations of gut barrier integrity and microbiota composition. Paired evaluations of gut functions revealed that the treatment with BuNa restored PTX-induced altered gut barrier integrity, microbiota composition and food intake suggesting a gut-to-brain communication. The treatment with BuNa also ameliorated depressive- and anxiety-like behaviors induced by PTX in mice, and these effects were associated with neuroprotective and anti-inflammatory outcomes. These results propose that diet supplementation with this safe postbiotic might be considered when managing PTX-induced central side effects during cancer therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Microbioma Gastrointestinal / Enteropatias / Neoplasias Pulmonares Limite: Animals Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Microbioma Gastrointestinal / Enteropatias / Neoplasias Pulmonares Limite: Animals Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2022 Tipo de documento: Article